The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Azacitidine with checkpoint inhibitors for AML and MDS
There has been growing evidence that the combination of hypomethylating agents like azacitidine with immune checkpoint inhibitors could be a highly potent treatment option in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We interviewed Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, at the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, about his recent studies exploring this combination. He discusses the data from these trials, including NCT02397720, highlighting the key findings, as well as the close relationship between pre-therapy CD3 and CD8 presence in the bone marrow with response rate. He explains how this correlation implies that future studies could use bone marrow CD3/8 as biomarkers to predict which patients would respond best to this treatment, greatly increasing its efficacy.
